XML 32 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Related-party Transactions
 6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
Related-party Transactions Related-party Transactions
In September 2021, the Company entered into a sublease with Sonoma (“Sonoma Sublease”), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr. Klausner, the Chair of the Company’s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $4.6 million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both June 30, 2023 and December 31, 2022, there were accrued liabilities and other current liabilities of $0.5 million, and as of June 30, 2023 and December 31, 2022, there were other non-current liabilities of $3.3 million and $3.5 million, respectively, in connection with the Sonoma Sublease. Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in “other operating income, net” such as common area maintenance charges. See Note 7, Leases, for more detail on the Sonoma Sublease.
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
Sonoma other operating income, net$648 $658 $1,317 $1,317 
Sonoma sublease income$464 $466 $930 $931 
The Company was party to the GSK Agreement with GSK, which is a holder of more than 10% of the Company’s outstanding common stock. See Note 3, License, Collaboration and Success Payment Agreements. GSK terminated the GSK Agreement effective December 24, 2022. The Company had no current or non-current deferred revenue in connection with the GSK Agreement as of both June 30, 2023 and December 31, 2022. Revenue recognized in connection with the GSK agreement was zero and $35.7 million for the three months ended June 30, 2023 and 2022, respectively, and zero and $36.3 million for the six months ended June 30, 2023 and 2022, respectively.